# EDGAR Filing Document

**Accession Number:** 0001831915
**File Stem:** 0001193125-26-011748
**Filing Date:** 2026-1
**Character Count:** 12781
**Document Hash:** 2c5a7b12df06e015214bb9e54033da2e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-011748.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001193125-26-011748

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cytek Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001831915
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472547526
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40632
- **FILM NUMBER:** 26530218

**BUSINESS ADDRESS:**
- **STREET 1:** 47215 LAKEVIEW BOULEVARD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538
- **BUSINESS PHONE:** (877) 922-9835

**MAIL ADDRESS:**
- **STREET 1:** 47215 LAKEVIEW BOULEVARD
- **CITY:** FREMONT
- **STATE:** CA
- **ZIP:** 94538

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cytek BioSciences, Inc.
- **DATE OF NAME CHANGE:** 20201110

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported):

#### January 12, 2026

## Cytek Biosciences, Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40632** | **47-2547526** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |
| **47215 Lakeview Boulevard**<br> **Fremont, California** | **47215 Lakeview Boulevard**<br> **Fremont, California** | **94538** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (877) 922-9835

#### (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.001 per share | CTKB | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On January 12, 2026, Cytek Biosciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description of Exhibit** |
| 99.1 | [Press release dated January 12, 2026](d41645dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Cytek Biosciences, Inc.** | **Cytek Biosciences, Inc.** |
| &nbsp;&nbsp;&nbsp;&nbsp; Date: January 13, 2026 | By: | /s/ Wenbin Jiang |
|  |  | Wenbin Jiang, Ph.D.<br> President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results** 

**Company to present at the 44<sup>th</sup> Annual JP Morgan Healthcare Conference** 

FREMONT, Calif., January 12, 2026 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.

Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.

"Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025 and reflects a continuation of positive trends we saw emerging in the third quarter. These trends include a continuation of strong growth in Services, Reagents and Asia Pacific instrument revenue and an improvement in instrument revenue growth in the US and EMEA<sup>1</sup>. We were particularly pleased to see a return to positive growth in our instrument sales in EMEA in the fourth quarter," said Dr. Wenbin Jiang, CEO of Cytek Biosciences. "With strong execution across our portfolio, we believe we are well positioned to deliver sustainable growth and profitability in a large flow cytometry market."

The preliminary financial results in this press release are not a comprehensive statement of Cytek's financial results for the fourth quarter and full year ended December 31, 2025, and have not been audited, reviewed or compiled by its independent registered public accounting firm. Cytek's actual revenue may differ from the estimate due to the completion of the Company's year-end closing and auditing procedures and is therefore subject to adjustment. Cytek plans to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide 2026 financial guidance during its earnings call expected to be held near the end of February 2026.

<u>J.P. Morgan Healthcare Conference</u> 

Cytek will participate and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday January 14, 2026, at 5:15 PM Pacific Time / 8:15 PM Eastern Time. Interested parties may access live and archived webcasts of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.

**About Cytek Biosciences, Inc.** 

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling<sup>™</sup> (FSP<sup>®</sup>) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora<sup>™</sup>, Northern Lights<sup>™</sup>, Cytek Aurora<sup>™</sup> CS and Cytek Aurora<sup>™</sup> Evo systems; the Cytek Orion<sup>™</sup> reagent cocktail preparation system; the Enhanced Small Particle<sup>™</sup> (ESP<sup>™</sup>) detection technology; the flow cytometers and imaging products under the Amnis<sup>®</sup> and Guava<sup>®</sup> brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at <u>www.cytekbio.com</u>.

1. EMEA = Europe, Middle East, and Africa

------

Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

**Forward-Looking Statements** 

------

adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled "Risk Factors" set forth in Cytek's Quarterly Report on Form 10-Q filed on November 5, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release.

**Media Contact:** 

Stephanie Olsen

Lages & Associates

(949) 453-8080

<u>stephanie@lages.com</u> 

**Investor Contact:** 

Paul Goodson

Head of Investor Relations

Cytek Biosciences

<u>pgoodson@cytekbio.com</u>